Targeted delivery of anti-tuberculosis drugs to macrophages: targeting mannose receptors

Abstract

The development of systems for targeted delivery of anti-tuberculosis drugs is a challenge of modern biotechnology. Currently, these drugs are encapsulated in a variety of carriers such as liposomes, polymers, emulsions and so on. Despite successful in vitro testing of these systems, virtually no success was achieved in vivo, because of low accessibility of the foci of infection located in alveolar macrophage cells. A promising strategy for increasing the efficiency of therapeutic action of anti-tuberculosis drugs is to encapsulate the agents into mannosylated carriers targeting the mannose receptors of alveolar macrophages. The review addresses the methods for modification of drug substance carriers, such as liposomes and biodegradable polymers, with mannose residues. The use of mannosylated carriers to deliver anti-tuberculosis agents increases the drug circulation time in the blood stream and increases the drug concentration in alveolar macrophage cells. The bibliography includes 113 references.

Computer simulation of the Receptor–Ligand Interactions of Mannose Receptor CD206 in Comparison with the Lectin Concanavalin A Model

“…For creating effective treatment approaches for various diseases, including respiratory diseases, it is important not only to develop new pharmaceuticals, but also their targeted delivery to the affected tissues and cells [ 2 ]. Mϕ can serve as targets, which play an important role in the immune response due to recognition and killing pathogens [ 3 ]. However, Mϕ can also be a reservoir for growth and reproduction of bacteria and viruses that significantly limits efficiency of antibiotics and of antiviral therapy [ 4 , 5 ].…”

Nanotechnology‐Based Targeted Drug Delivery: An Emerging Tool to Overcome Tuberculosis

“…Different functionalization strategies were developed for mannosylation including the synthesis of mannose–nanocarrier building block conjugates followed by nanocarrier formation, covalent functionalization of the formed nanocarriers, and physical adsorption of mannose to the surface of the nanocarriers. [ 105,106 ] Recent findings on active targeting of anti‐TB‐drug‐loaded nanocarriers via macrophage mannose receptor are summarized in Table 3 .…”

“…Different functionalization strategies were developed for mannosylation including the synthesis of mannose-nanocarrier building block conjugates followed by nanocarrier formation, covalent functionalization of the formed nanocarriers, and physical adsorption of mannose to the surface of the nanocarriers. [105,106] Recent findings on active targeting of anti-TB-drug-loaded nanocarriers via macrophage mannose receptor are summarized in Inhalable, RIF-loaded mannosylated SLNs were developed to target AMs by dry powder inhaler device. Mannosylated fatty acid derivatives with a dual role of functionalizing agents and surfactants were incorporated into SLNs.…”

A review on chitosan and its development as pulmonary particulate anti-infective and anti-cancer drug carriers

“…Liquid dosage form such as nanoemulsion commonly exhibits a high level of dispersion and inhalation to peripheral lungs ( Amani et al, 2010 ; Shah et al, 2017 ). The alveolar macrophages are characterized by cell surface leptin receptor of mannose specificity ( Filatova et al, 2018 ). The chitosan is known to be able to be recognized by alveolar macrophages.…”